Diyaliz hastalarında plazma ghrelin düzeyinin malnüttrisyon ile ilişkisi

Ghrelin, ana olarak midedeki endokrin hücrelerde sentezlenen yeni bir homondur. Öncelikle güçlü bir büyüme hormonu salgılatıcı hormon olarak tanımlanmış olmasına karşın insanlarda, iştah ve vücut ağırlığının fizyolojik bir düzenleyicisi olduğu anlaşılmıştır. Ghrelin salgısının böbrek yetmezliği olan hastalarda değiştiği bilinmektedir. Çalışmamızda, kronik böbrek yetmezliği hastalarında serum ghrelin düzeylerini ölçmeyi ve belirli nütrisyonel ve inflamatuar belirteçlerle ilişkisini araştırmayı amaçladık. Çalışmaya 28 hemodiyaliz (HD) ve 30 periton diyalizi (PD) hastası alındı. Hastaların serum ghrelin düzeyleri yaş ve cinsiyet olarak eş 21 sağlıklı gönüllü ile karşılaştırıldı. Hastaların serum ghrelin düzeyi dışında yaş, cinsiyet, diyaliz süresi, vücut kitle indeksi (VKİ), serum albumin, total kolesterol, LDL, HDL, trigliserid, intakt paratiroid hormon (iPTH), C-reaktif protein (CRP), serum demir bağlama kapasitesi (SDBK), BUN, kreatinin, periton sıvısı BUN, kreatinin, albumin düzeyleri gibi demografik ve laboratuvar verileri değerlendirildi. Subjektif global değerlendirme (SGD) ve malnütrisyon inflamasyon skoru (MİS) tüm hastalara uygulandı. Serum ghrelin düzeyleri hem HD (42,8±30,1 pg/ml, P=,000) hem de PD (28,5±15,0 pg/ml , P=,000) hastalarında sağlıklı kontrol grubuna (15,6±5,7 pg/ml) göre yüksek saptandı ancak iki diyaliz grubu arasında anlamlı fark bulunamadı (P=,02; Benferroni düzeltmesine göre P<0,016 anlamlı). Hastaların laboratuvar verileri karşılaştırıldığında PD hastalarında ghrelinin hiçbir parametre ile anlamlı korelasyon göstermediği HD hastalarında ise MİS ile pozitif, albumin değeriyle ise negatif bir korelasyon gösterdiği bulundu. Subjektif global değerlendirme testine göre iyi beslenmiş hastalarla malnütrisyonlu hastaları karşılaştırdığımızda malnütrisyonlu hastaların ghrelin düzeylerinin daha yüksek olduğu (P=0,026), VKİ’lerinin (P=0,000) ve trigliserid düzeylerinin (P=0,008) daha düşük olduğu saptandı. Ghrelin düzeyine etki ettiği düşünülen nütrisyonel ve inflamatuar parametreler ile bir multipl lojistik regresyon modeli yapıldığında ise sadece MİS değerinin anlamlı olduğu görüldü (P=0,042). Serum ghrelin düzeyi hem HD hem de PD hastalarında benzer şekilde yükselmektedir. Hastanın nütrisyonel durumu ghrelin düzeyi üzerinde güçlü bir belirleyicidir. Malnütrisyon kronik HD ve PD tedavisi altındaki hastalarda serum ghrelin düzeyini artırmaktadır

The long-term outcome of microsurgical end-to-side anastomosis technique in the management of renal grafts with multiple arteries

WOS: 000367726702547

THE ASSESSMENT OF RENAL TRANSPLANT PATIENTS REGARDING MICRO-ELIMINATION OF CHRONIC VIRAL HEPATITISES IN TURKEY: AN ANALYSIS OF 2410 PATIENTS

WOS: 000491488703132[No abstract available

COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic

Background Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47-66]), first- (56 mL/min [IQR, 51-68]), third- (51 mL/min [IQR,48-67]) and sixth-months (52 mL/min [IQR, 48-81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode

COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul.

© 2020 Wiley Periodicals LLCIntroduction: Management of COVID-19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy. However, there is no consensus on this issue yet. This study aimed to our experiences with kidney transplant recipients diagnosed with COVID-19. Material and Methods: Kidney transplant recipients diagnosed with COVID-19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Patients were classified as having moderate or severe pneumonia for the analysis. The primary endpoint was all-cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation. Results: Forty patients were reviewed retrospectively over a follow-up period of 32 days after being diagnosed with COVID-19. Cough, fever, and dyspnea were the most frequent symptoms in all patients. The frequency of previous induction and rejection therapy was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. None of the patients using cyclosporine A developed severe pneumonia. Five patients died during follow-up in the intensive care unit. None of the patients developed graft loss during follow-up. Discussion: COVID-19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients. Immunosuppression should be carefully reduced in these patients. Induction therapy with lymphocyte-depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period

Fabry Disease Prevalence in Renal Replacement Therapy in Turkey

Background: Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from lack of alpha-galactosidase A (AGALA) activity in lysosomes. Objective: In this multicenter study, we aimed to evaluate the prevalence of FD in renal transplant (Tx) recipients in Turkey. We also screened dialysis patients as a control group. Methods: All Tx and dialysis patients were screened regardless of the presence of a primary disease. We measured the AGALA activity in all male patients as initial analysis. Mutation analysis was performed in male patients with decreased AGALA activity and in female patients as the initial diagnostic assay. Results: We screened 5,657 patients. A total of 17 mutations were identified. No significant difference was observed between the groups regarding the prevalence of patients with mutation. We found FD even in patients with presumed primary kidney diseases. Seventy-one relatives were analyzed and mutation was detected in 43 of them. We detected a patient with a new, unknown mutation (p.Cys223) in the GLA gene. Conclusions: There are important implications of the screening. First, detection of the undiagnosed patients leads to starting appropriate therapies for these patients. Second, the transmission of the disease to future generations may be prevented by prenatal screening after appropriate genetic counseling. In conclusion, we suggest screening of kidney Tx candidates for FD, regardless of etiologies of chronic kidney disease. (C) 2019 S. Karger AG, Base

Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study

Background In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different